8-K: MetaVia Inc. Announces 1-for-11 Reverse Stock Split

MetaVia Inc. will implement a 1-for-11 reverse stock split effective December 4, 2025, to meet Nasdaq's continued listing requirements.

Summary

• Stockholders approved a proposal to amend the company's Certificate of Incorporation to effect a reverse stock split at a ratio in the range of 1-for-5 to 1-for-30 on June 30, 2025.
• The Board of Directors approved a 1-for-11 reverse stock split on November 22, 2025.
• The company filed a Certificate of Amendment with the Delaware Secretary of State on December 2, 2025, to effect the Reverse Stock Split.
• The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on December 4, 2025.
• The Common Stock is expected to begin trading on a split-adjusted basis on Nasdaq when the market opens on December 5, 2025.
• Every 11 shares of the company's issued and outstanding Common Stock will automatically be combined into one share.
• The number of authorized shares of common stock will remain at 100 million, while the number of outstanding shares will be reduced from approximately 25.4 million to approximately 2.3 million.
• Fractional shares will be rounded down to the next whole share, with stockholders receiving cash equal to the market value of the fractional share.
• A proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, restricted stock units, and warrants.
• The Common Stock will continue to trade under the symbol "MTVA", and the new CUSIP number will be 64132R 503.

Sentiment

Score: 4

Explanation: The reverse stock split addresses a critical Nasdaq listing requirement, which is a necessary step to avoid delisting. However, the underlying reason for the split (low stock price) indicates negative market sentiment and potential operational challenges, which are not directly improved by the split itself. The company is a clinical-stage biotech, which inherently carries high risk and volatility.

Positives

• The reverse stock split addresses Nasdaq's continued listing requirements, preventing potential delisting and maintaining the company's presence on a major exchange.

Negatives

• Reverse stock splits are often perceived negatively by the market, indicating a low stock price and underlying challenges that necessitated the action.
• The need for a reverse split suggests the company's stock price has fallen below Nasdaq's minimum bid price requirement, which can signal investor concern.

Risks

• Actual events or results may differ materially from forward-looking statements due to various factors.
• Risks are associated with MetaVia's ability to execute on its commercial strategy.
• Uncertainty exists regarding the sufficiency of existing cash on hand to fund MetaVia's operations.
• There are risks related to the timeline for regulatory submissions and the ability to obtain regulatory approval through the development steps of product candidates.
• The company relies on the cooperation of its contract manufacturers, clinical study partners, and others involved in product development.
• Potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment.
• Risks include MetaVia's ability to initiate and complete clinical trials on a timely basis and to recruit subjects for its clinical trials.
• There is no guarantee that clinical trial results will be consistent with the results of pre-clinical and previous clinical trials.
• Impact of costs related to license agreements, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement.
• The effects of changes in applicable laws or regulations could negatively impact the company.
• Changes to MetaVia's stock price could affect the terms of license agreements and any future fundraising efforts.

Future Outlook

The company expects its common stock to begin trading on a split-adjusted basis on Nasdaq starting December 5, 2025. Forward-looking statements are subject to various risks and uncertainties, and actual results may differ materially from current expectations.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer, duly authorized the execution of the Certificate of Amendment on December 2, 2025.

Industry Context

Reverse stock splits are a common strategy employed by companies, particularly in the biotechnology sector, to maintain compliance with stock exchange listing requirements, such as Nasdaq's minimum bid price rule. While addressing a critical listing issue, such actions often reflect underlying challenges with stock valuation and investor confidence, which can be a concern for a clinical-stage company like MetaVia Inc. developing treatments for cardiometabolic diseases.

Comparison to Industry Standards

• Many companies, especially those in the volatile biotechnology sector, face challenges maintaining minimum bid prices on exchanges like Nasdaq. Reverse splits are a standard mechanism to address this, similar to how other clinical-stage biotechs might consolidate shares to boost per-share price.
• For example, companies like Sorrento Therapeutics (SRNE) or Athersys (ATHX) have also executed reverse stock splits to maintain Nasdaq compliance, often following periods of significant stock price decline due to clinical trial outcomes or funding challenges.
• The 1-for-11 ratio is within the typical range (often 1-for-5 to 1-for-30) seen in similar situations, aiming to achieve a sustainable per-share price above the $1 minimum.

Corporate Governance

Stakeholder Impact

• Shareholders: Will see their number of shares reduced by a factor of 11, with a proportionate increase in share price. Fractional shares will be cashed out. The overall value of their holdings should theoretically remain the same immediately after the split, but the action itself often signals underlying issues.
• Employees (with equity incentives): Stock options, restricted stock units, and warrants will be proportionately adjusted in terms of exercise price and number of shares, maintaining their intrinsic value.
• Nasdaq: The action aims to satisfy Nasdaq's continued listing requirements, maintaining the company's presence on the exchange.

Next Steps

• Common Stock to begin trading on a split-adjusted basis on Nasdaq on December 5, 2025.
• Equiniti Trust Company, LLC will act as the exchange agent for the Reverse Stock Split.
• Continued development of DA-1726 for obesity and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to maintain Nasdaq listing compliance, preventing a potential delisting event. While it addresses a technical requirement, it does not fundamentally alter the company's business operations or financial health. The company remains a clinical-stage biotechnology firm with inherent high risks and potential for significant volatility based on clinical trial outcomes for its cardiometabolic disease treatments. Investors should hold to observe the impact of the split on market perception and await further operational and clinical development updates, as the long-term value will depend on its drug pipeline success rather than this structural change.

Keywords

Reverse Stock Split, Nasdaq Listing Compliance, MTVA, MetaVia Inc., Common Stock, Biotechnology, Cardiometabolic Diseases, Obesity, MASH, DA-1726, Vanoglipel, GLP1R, GCGR, GPR119